UroGen Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities | ||
| Net loss | $(153,494) | $(126,874) |
| Adjustment to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 307 | 329 |
| Accrued financing on prepaid forward obligation | 2,865 | 15,077 |
| Accretion on marketable securities | (1,875) | (2,891) |
| Share-based compensation | 11,959 | 13,108 |
| Amortization (accretion) of discount on long-term debt | 476 | (1,305) |
| Amortization of right-of-use assets | 2,104 | 857 |
| Acquisitions of IPR&D | 3,128 | — |
| Changes in operating assets and liabilities: | ||
| Inventory | (7,237) | (3,554) |
| Accounts receivable, net | (12,780) | (4,859) |
| Prepaid expenses and other current assets | (5,827) | 1,436 |
| Other non-current assets | (4,572) | 1,449 |
| Accounts payable and accrued expenses | 286 | 10,893 |
| Employee related accrued expenses | 2,946 | (244) |
| Other current liabilities | (202) | 200 |
| Lease liabilities | (639) | (1,034) |
| Restricted deposit | (1) | 49 |
| Uncertain tax positions | 112 | 597 |
| Net cash used in operating activities | (162,444) | (96,766) |
| Cash Flows From Investing Activities | ||
| Purchases of marketable securities | (77,400) | (128,023) |
| Maturities of marketable securities | 139,247 | 107,705 |
| Purchases of property and equipment | (289) | (295) |
| Net cash provided by (used in) investing activities | 61,558 | (20,613) |
| Cash Flows From Financing Activities | ||
| Principal payments on finance leases | (1,855) | — |
| Proceeds from exercise of options into ordinary shares | 1,972 | 321 |
| Proceeds from issuance of long-term debt, net of issuance costs | — | 24,488 |
| Proceeds from pre-funded warrant issuance, net of issuance costs | — | 18,641 |
| Proceeds from ordinary shares issuances, net of issuance costs | 39,801 | 151,169 |
| Net cash provided by financing activities | 39,918 | 194,619 |
| Increase (Decrease) in Cash and Cash Equivalents | (60,968) | 77,240 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year | 173,063 | 95,823 |
| Cash, Cash Equivalents and Restricted Cash at End of Year | $112,095 | $173,063 |
| Supplemental Disclosures of Non-Cash Activities | ||
| Right-of-use assets obtained in exchange for new operating and finance lease liabilities | $7,427 | $2,321 |
| Acquisitions of IPR&D | $3,128 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.